Invalidity dossier
US 10550085
Deuterated compounds and uses thereof
Current assignee: Aldeyra Therapeutics Inc
Added 9/23/2026, 9:35:36 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 10,550,085 B2
Title: Deuterated compounds and uses thereof
Patent number: US10550085B2 (application US15/754,065; also published as US20180354905A1)
Assignee: Aldeyra Therapeutics, Inc. (listed as both original and current assignee; inventors Todd Brady, Scott Young, William A. Kinney, and Susan Macdonald assigned rights to Aldeyra Therapeutics, Inc. per the recorded assignment dated 2018‑05‑23).
Key dates (as listed): Priority date 2015‑08‑21; filing date 2016‑08‑22; publication date 2020‑02‑04; anticipated expiration 2036‑08‑22. Legal status listed as Active, with the source noting this is an assumption and not a legal conclusion.
Purpose: The patent concerns deuterated chemical compounds and their uses. Per the source's "Prior art keywords," the subject matter relates to a compound, deuterium, treatment, hydrogen peroxide, and disease.
Plain-language scope: The disclosure centers on a chemical genus represented by a Markush structure — a chlorinated quinoline-type core bearing an amino group and a side chain of the form C(R³)(R⁴)–O–R² — together with numerous specific deuterated species. Representative examples include deuterated analogs of a chloro-quinolinamine compound in which deuterium ([²H]) is placed at defined ring positions and/or in a methyl group of the side chain (e.g., C(C)(O)C([²H])([²H])[²H]). The source lists multiple individual deuterated compounds, mixtures, and related intermediates, and refers to uses in treatment. The claims themselves are not reproduced in this excerpt, so the precise metes and bounds of the claimed subject matter are not established here.
What the excerpt does not establish: It does not provide the granted claim text, the specification's detailed description, dosages, specific diseases, or experimental data. It does not establish any litigation, ownership transfer beyond the recorded assignment, validity, enforceability, or the content or teaching of any prior-art reference. The chemical structures shown are limited to those appearing in the excerpt.
Generated 10/1/2026, 9:34:11 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10550085. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.